This article features deals sourced directly by Gizmodo and produced independently of the editorial team. We may earn a commission when you buy through links on the site. Reading time 3 minutes ...

Please provide your email address to receive an email when new articles are posted on . Physicians prescribing GLP-1 therapies should start at the lowest dose and titrate slowly to lessen ...

Two of the largest clinical trials of their kind have doused hopes that a diabetes and weight loss “wonder drug” might also work its magic on Alzheimer’s. A daily dose of oral semaglutide did not ...

Employers have cut more than 1.1 million jobs through November, the most since 2020, when companies laid off 2.2 million workers as the pandemic was slamming the U.S. economy, according to a new ...

The U.S. and global economies are set to slow next year as higher tariffs take full effect, but could grow more strongly than expected if the AI investment boom “broadens,” the Organization for ...

Check out the Air Force 1 Gore-Tex in this detailed review, including its waterproof performance and all-day comfort. See how these iconic sneakers hold up in wet conditions and whether they live up ...

Artificial intelligence is disrupting the workforce, but reports about how that’s happening have been confusing, taken out of context—or used to prove doom-and-gloom scenarios that are unlikely to ...

“We felt we had a responsibility to explore semaglutide’s potential, despite a low likelihood of success,” Martin Holst Lange, Novo’s R&D chief, said on Monday. Novo Nordisk’s semaglutide did not ...

Top-line results from two large clinical trials by Novo Nordisk, the company behind Ozempic and Wegovy, found oral semaglutide failed to slow down Alzheimer's progression Endocrinologist Daniel ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression of Alzheimer’s disease in closely watched trials, drugmaker Novo Nordisk ...

Upcoming data from Novo Nordisk A/S (NYSE: NVO) early next month could offer the clearest signal yet on whether GLP-1 medicines — widely used for diabetes and weight loss — can also slow the ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Within the next two weeks ...